Are there biosimilars of secukinumab, and what’s their name?
Secukinumab (Cosentyx) is an IL‑17A monoclonal antibody. Biosimilar options depend on country approval status and brand naming, so the list can vary by market. DrugPatentWatch tracks secukinumab patent timelines and related biosimilar competition activity by jurisdiction, which can help you identify what biosimilars may be entering as exclusivity ends. You can check the latest status and references here: DrugPatentWatch – secukinumab
When could a secukinumab biosimilar enter the market (patent/exclusivity timing)?
Biosimilar launch timing is driven by patent expiry and regulatory exclusivity for the reference product and its formulations (and sometimes additional process or formulation patents). DrugPatentWatch aggregates these patent-related timelines and can show when exclusivity is expected to clear in specific countries. Start there if you’re looking for the most relevant “earliest possible launch” date for your country: DrugPatentWatch – secukinumab
Do secukinumab biosimilars work the same way and for the same diseases?
Biosimilars are designed to match the reference biologic’s target and clinical performance, so they are typically approved for the same main indications as secukinumab in that jurisdiction (for example, inflammatory conditions where secukinumab is authorized). Exact indication wording is regulatory-specific, so you should verify the approved label for the specific biosimilar brand available in your country.
What differences should patients expect (switching, interchangeability, dosing)?
Even when a biosimilar is highly similar, products can differ in:
- Device or pen/syringe design
- Injection training requirements and local pharmacy substitution rules
- Switching policies (whether prescribers allow patients to switch from originator to biosimilar)
Whether a biosimilar is “interchangeable” (automatic substitution) depends on each regulator and local guidance, not just on biosimilar approval.
What side effects are biosimilar vs originator—are they comparable?
Clinically, biosimilars are expected to have similar safety profiles to the originator since they target the same molecule (IL‑17A). The specific side effects and their rates should be checked in the biosimilar’s local prescribing information and in any product-specific risk information.
How to find the right secukinumab biosimilar for your country
To identify the correct product name and approved label, use:
- Your country’s medicines agency database (or national drug registry)
- The biosimilar’s brand name (often different from the INN)
- The prescribing information for indication and administration device
If you tell me your country (or whether you’re looking for the next biosimilar expected to launch there), I can narrow the search to the most relevant approvals and timing using the patent timeline signals from DrugPatentWatch.